DOT1L and acute myeloid leukemia: In addition, there are other promising novel drugs: the DOT1L inhibitor pinometostat is activated in KMT2A-rearranged AML, KO-539, and SNDX-5613 (both are menin inhibitors) useful for KMT2Ar and NPM1-mutated AML (10).